Longeveron Inc (LGVN)

$0.63 0.00 (-0.60%)
Market Cap 13.58M
Revenue (ttm) 2.39M
Net Income (ttm) -15.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -668.20%
Debt to Equity Ratio 0.00
Volume 277,700
Avg Vol 477,988
Day's Range N/A - N/A
Shares Out 21.33M
Stochastic %K 47%
Beta 0.18
Analysts Strong Sell
Price Target $6.86

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
Banelamhh
Banelamhh Dec. 4 at 6:07 PM
$LGVN
0 · Reply
Banelamhh
Banelamhh Dec. 4 at 2:51 PM
$LGVN $1
0 · Reply
Roaring_Capybara
Roaring_Capybara Dec. 3 at 6:09 PM
$LGVN Accumulating.
0 · Reply
Tommyj1014
Tommyj1014 Dec. 3 at 4:02 PM
$LGVN
0 · Reply
Dorps332
Dorps332 Dec. 3 at 3:50 PM
$LGVN maybe Josh Hare can find away to turn this around and find a partner in the next few weeks!
0 · Reply
Stmkr
Stmkr Dec. 3 at 3:15 PM
$LGVN Another cell therapy with good science that I think will work out $CAPR Major readout in 2026 Eligible for PRV
0 · Reply
poilu
poilu Dec. 3 at 1:55 PM
$LGVN Maybe my expectations were too high...but I was hoping for more than a penny on yesterday's news.
1 · Reply
SpartanVI
SpartanVI Dec. 3 at 10:41 AM
$LGVN holding full Will have a move soon
0 · Reply
SpartanVI
SpartanVI Dec. 3 at 8:54 AM
Today's watch $LGVN had pr yesterday, getting found Known runner , Room to 1$+ if .80.break $PMAX nice close yesterday 3.5$KEY $CMCT pr in AH but didnt do much Needs 4.2 break
0 · Reply
profitabletrader1234
profitabletrader1234 Dec. 3 at 8:28 AM
$LGVN $LONGEVERON Inc ​ Massive news on patent..... 🚀🚀🚀🚀🚀🚀​
0 · Reply
Latest News on LGVN
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 2, 2025, 9:15 AM EST - 2 days ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Dec 1, 2025, 12:00 PM EST - 3 days ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 15 days ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 12, 2025, 9:05 AM EST - 22 days ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:36 PM EST - 4 weeks ago

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 27, 2025, 9:15 AM EDT - 5 weeks ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 6, 2025, 9:15 AM EDT - 2 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 2 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 3 months ago

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 3 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 10:55 PM EDT - 4 months ago

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 4 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 4 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 4 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 4 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 5 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 5 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 5 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 6 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 7 months ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 7 months ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 9, 2025, 5:31 PM EDT - 7 months ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 7 months ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 7 months ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 9 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 9 months ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:04 PM EST - 9 months ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 9 months ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 10 months ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:37 PM EST - 1 year ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:58 PM EDT - 1 year ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 11:38 AM EDT - 1 year ago

Longeveron stock opened 100% up on Wednesday: explore why

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Neha Motwani Elected to Longeveron® Board of Directors

Jul 9, 2024, 9:00 AM EDT - 1 year ago

Neha Motwani Elected to Longeveron® Board of Directors

Banelamhh
Banelamhh Dec. 4 at 6:07 PM
$LGVN
0 · Reply
Banelamhh
Banelamhh Dec. 4 at 2:51 PM
$LGVN $1
0 · Reply
Roaring_Capybara
Roaring_Capybara Dec. 3 at 6:09 PM
$LGVN Accumulating.
0 · Reply
Tommyj1014
Tommyj1014 Dec. 3 at 4:02 PM
$LGVN
0 · Reply
Dorps332
Dorps332 Dec. 3 at 3:50 PM
$LGVN maybe Josh Hare can find away to turn this around and find a partner in the next few weeks!
0 · Reply
Stmkr
Stmkr Dec. 3 at 3:15 PM
$LGVN Another cell therapy with good science that I think will work out $CAPR Major readout in 2026 Eligible for PRV
0 · Reply
poilu
poilu Dec. 3 at 1:55 PM
$LGVN Maybe my expectations were too high...but I was hoping for more than a penny on yesterday's news.
1 · Reply
SpartanVI
SpartanVI Dec. 3 at 10:41 AM
$LGVN holding full Will have a move soon
0 · Reply
SpartanVI
SpartanVI Dec. 3 at 8:54 AM
Today's watch $LGVN had pr yesterday, getting found Known runner , Room to 1$+ if .80.break $PMAX nice close yesterday 3.5$KEY $CMCT pr in AH but didnt do much Needs 4.2 break
0 · Reply
profitabletrader1234
profitabletrader1234 Dec. 3 at 8:28 AM
$LGVN $LONGEVERON Inc ​ Massive news on patent..... 🚀🚀🚀🚀🚀🚀​
0 · Reply
Paraboljoker
Paraboljoker Dec. 3 at 12:44 AM
$PMAX and $LGVN , big news
0 · Reply
SpartanVI
SpartanVI Dec. 2 at 11:05 PM
$LGVN $PRZO $KTTA $FLYE $SMX ⏰️🔥
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Dec. 2 at 11:04 PM
$LGVN 👀
0 · Reply
dbr_island
dbr_island Dec. 2 at 10:59 PM
🚨EPOW🚨NEWS JUST OUT AH🚨 PT: $2 🎯✅ $FCHL $TVRD $LGVN $YGMZ $ABTC watching closely
2 · Reply
Paraboljoker
Paraboljoker Dec. 2 at 10:55 PM
$LGVN .67 Ready to go parabolic
0 · Reply
Paraboljoker
Paraboljoker Dec. 2 at 10:47 PM
$LGVN .68 new $KALA $PRZO $AMED $PMAX
0 · Reply
Paraboljoker
Paraboljoker Dec. 2 at 10:41 PM
$LGVN Easy overnight $PRZO $KTTA $FLYE $SMX
0 · Reply
Paraboljoker
Paraboljoker Dec. 2 at 10:33 PM
$LGVN Due for a pop🗞️ $PRZO $KTTA $FLYE $SMX
0 · Reply
SpartanVI
SpartanVI Dec. 2 at 10:30 PM
$LGVN overnight idea Premarket potential
1 · Reply
Paraboljoker
Paraboljoker Dec. 2 at 10:20 PM
$AEMD $LGVN Market not known to be reasonable, soon they find LGVN
0 · Reply
Tommyj1014
Tommyj1014 Dec. 2 at 10:02 PM
$LGVN no walls, let's push
0 · Reply
EC100
EC100 Dec. 2 at 10:00 PM
$LGVN needs to break .70
0 · Reply